NSETrading Window4h ago · 25 Sept 2026, 02:42 pm
Trading Window
GlaxoSmithKline Pharmaceuticals Limited · GLAXO
✦ AI SummaryResults
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of its Q2 and H1 FY2026-27 financial results.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Attachments (1)
📄pdf
Download →
GLAXO1924_25092026144154_Tradingwindowclosure.pdf
View document text
GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Web: www.gsk-india.com
Email: askus@gsk.com
25th September 2026
BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Dalal Street Bandra-Kurla Complex, Bandra (East)
Mumbai - 400001 Mumbai - 400051
Dear Sir,
Sub: Closure of “Trading Window”
We wish to inform you that in terms of the provisions of SEBI (Prohibition of Insider Trading)
Regulations 2015, the trading period for buying or selling of Company's shares is closed from
Thursday, 1st October 2026 till 48 hours after the announcement/declaration of the Un-audited
Financial Results of the Company for the second quarter and half year ended 30th September
2026.
The date of Board Meeting for declaration of the Un-Audited Financial Results of the Company
for the second quarter and half year ended 30th September 2026 will be intimated in due course.
Kindly take same on record.
Thanking you,
Yours faithfully
For GlaxoSmithKline Pharmaceuticals Limited
Ajay Nadkarni
Vice President – Administration,
Real Estate & Company Secretary
CIN No. L24239MH1924PLC001151